Preclinical efficacy and intermediate endpoint biomarkers: effects of weekly or intermittent dosing regimens of egfr, MEK and PI3K inhibitors in mouse models of lung cancer

Ended Awarded Last action

Contract number
HHSN26100007
Awardee
Awarding agency
Obligated
$647,739

Award facts

Opportunity
Contract value 100% obligated
$647,739.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Oklahoma City, OK 73104, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 5 $0
Other Administrative Action 4 $0
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $647,739

Quick answers

Who was awarded contract HHSN26100007?

HHSN26100007 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 19, 2013.

How much is contract HHSN26100007 worth?

The government has obligated $647,739 on HHSN26100007.

Is contract HHSN26100007 an order under another contract?

Yes. HHSN26100007 is a delivery order under HHSN261201200013I, an indefinite delivery contract, on Preclinical Efficacy and Intermediate Endpoint Biomarkers.

Was contract HHSN26100007 competed?

The extent of competition for HHSN26100007 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login